LAVA Therapeutics (NASDAQ:LVTX) Sees Significant Decrease in Short Interest

LAVA Therapeutics (NASDAQ:LVTX) was the recipient of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 45,500 shares, a decrease of 22.5% from the December 15th total of 58,700 shares. Currently, 0.3% of the company’s stock are sold short. Based on an average daily volume of 112,000 shares, the short-interest ratio is presently 0.4 days.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Pathway Financial Advisors LLC increased its stake in LAVA Therapeutics by 70.8% in the 3rd quarter. Pathway Financial Advisors LLC now owns 102,500 shares of the company’s stock valued at $170,000 after buying an additional 42,500 shares during the last quarter. XTX Topco Ltd bought a new position in shares of LAVA Therapeutics in the second quarter valued at approximately $55,000. Finally, Virtu Financial LLC purchased a new stake in shares of LAVA Therapeutics during the third quarter valued at approximately $32,000.

Analyst Upgrades and Downgrades

Several analysts have recently commented on LVTX shares. HC Wainwright reduced their target price on LAVA Therapeutics from $6.00 to $2.00 and set a “buy” rating for the company in a research note on Friday, December 20th. JMP Securities reissued a “market perform” rating and issued a $6.00 price target on shares of LAVA Therapeutics in a research report on Wednesday, December 11th. Leerink Partnrs downgraded shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. Leerink Partners reiterated a “market perform” rating and set a $2.00 price objective (down from $11.00) on shares of LAVA Therapeutics in a report on Thursday, December 12th. Finally, Citizens Jmp lowered shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 11th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $3.33.

LAVA Therapeutics Price Performance

NASDAQ:LVTX traded up $0.00 during trading hours on Friday, hitting $0.94. 14,757 shares of the company traded hands, compared to its average volume of 123,351. The firm’s 50-day simple moving average is $1.31 and its 200-day simple moving average is $1.64. LAVA Therapeutics has a one year low of $0.88 and a one year high of $6.47.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.